Transducin (β)-like 1 X-linked receptor 1 promotes gastric cancer progression via the ERK1/2 pathway.
Gastric cancer (GC) is one of the most common types of cancer worldwide, and it involves extensive local tumour invasion, metastasis and poor prognosis. Understanding the mechanisms regulating the progression of GC is necessary for the development of effective therapeutic strategies. Transducin (β)-like 1 X-linked receptor 1 (TBL1XR1) is an important regulator controlling gene activation and repression, which has been thought to be involved in tumorigenesis. However, the role of TBL1XR1 in human GC remains largely unknown. Here, we find that TBL1XR1 is aberrantly expressed in human GC tissues, and TBL1XR1 levels are highly correlated with local tumour invasion, late tumor, lymph node, metastasis (TNM) stage and poor prognosis. Knockdown of TBL1XR1 by shRNA inhibits GC cell proliferation, migration, invasion, epithelial-mesenchymal transition (EMT) in vitro, as well as tumorigenesis and peritoneal metastasis in vivo, whereas overexpression of TBL1XR1 produces the opposite effects. These effects are mediated by activation of the ERK1/2 signalling pathway, and inhibition of this pathway with a specific ERK1/2 inhibitor (U0126) significantly impairs the tumour-promoting effects induced by TBL1XR1. Moreover, TBL1XR1 mediated ERK1/2 activation is dependent on the β-catenin/MMP7/EGFR signalling pathway. In conclusion, TBL1XR1 contributes to GC tumorigenesis and progression through the activation of the β-catenin/MMP7/EGFR/ERK signalling pathway and may act as a new therapeutic target for GC.
Department of Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
Q
Q
Zhou
Department of Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
X
X
Wang
Department of Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
Z
Z
Yu
Department of Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
X
X
Wu
Department of Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
X
X
Chen
Department of Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
J
J
Li
Department of Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
Z
Z
Zhu
Department of Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
B
B
Liu
Department of Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
L
L
Su
D000368:Aged; D000818:Animals; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000235:genetics; D049109:Cell Proliferation / Q000235:genetics; D004195:Disease Models, Animal; D018450:Disease Progression; D058750:Epithelial-Mesenchymal Transition; D066246:ErbB Receptors / Q000378:metabolism; D005260:Female; D015870:Gene Expression; D064593:Heterografts; D006801:Humans; D007150:Immunohistochemistry; D020935:MAP Kinase Signaling System; D008297:Male; D020783:Matrix Metalloproteinase 7 / Q000378:metabolism; D051379:Mice; D008875:Middle Aged; D060787:Neoplasm Grading; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D009687:Nuclear Proteins / Q000235:genetics* / Q000378:metabolism; D011379:Prognosis; D018160:Receptors, Cytoplasmic and Nuclear / Q000235:genetics* / Q000378:metabolism; D012097:Repressor Proteins / Q000235:genetics* / Q000378:metabolism; D015398:Signal Transduction; D013274:Stomach Neoplasms / Q000235:genetics* / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D047368:Tumor Burden; D051176:beta Catenin / Q000378:metabolism
D009687:Nuclear Proteins; D018160:Receptors, Cytoplasmic and Nuclear; D012097:Repressor Proteins; C473691:TBL1XR1 protein, human; D051176:beta Catenin; D066246:ErbB Receptors; D020783:Matrix Metalloproteinase 7
Exp Hematol. 2000 Nov;28(11):1286-96
11063877
Am J Clin Exp Urol. 2015 Apr 25;3(1):13-23
26069883
Science. 2012 Dec 21;338(6114):1619-22
23160955
Breast Cancer Res. 2014 Oct 24;16(5):465
25341494
Nat Cell Biol. 2008 Feb;10 (2):160-9
18193033
Elife. 2015 Sep 03;4:null
26274564
EMBO J. 2003 Mar 17;22(6):1336-46
12628926
Mol Cell. 2002 Mar;9(3):611-23
11931768
Curr Gastroenterol Rep. 2016 Jul;18(7):34
27184043
Oncogene. 2015 Nov 5;34(45):5607-16
25703330
Gut. 2015 Jan;64(1):26-36
24667177
Am J Med Genet A. 2014 Sep;164A(9):2335-7
24891185
Cell. 2004 Feb 20;116(4):511-26
14980219
Oncogene. 2011 Apr 21;30(16):1868-79
21151173
Cancer Res. 2009 Sep 15;69(18):7357-65
19706770
J Biol Chem. 2016 Feb 19;291(8):4166-77
26565021
Oncol Rep. 2015 Sep;34(3):1469-77
26151310
Mol Cell Biol. 2004 Apr;24(8):3337-46
15060155
J Clin Oncol. 2006 May 10;24(14):2137-50
16682732
Mol Cancer. 2014 Aug 22;13:195
25145705
Lung Cancer. 2007 Jun;56(3):307-17
17316888
Cancer Genet Cytogenet. 2001 Nov;131(1):48-53
11734318
Mol Cell. 2015 Apr 2;58(1):35-46
25728771
Mol Cell. 2011 Jul 22;43(2):203-16
21777810
Endocr Relat Cancer. 2014 Jan 16;21(1):127-42
24243687
Br J Cancer. 2006 Aug 7;95(3):331-8
16847471
Carcinogenesis. 2015 Nov;36(11):1363-71
26264654
Nat Rev Clin Oncol. 2013 Nov;10(11):643-55
24061039
Blood. 2009 Nov 5;114(19):4081-8
19738028
Br J Cancer. 2014 Jul 8;111(1):112-24
24874481
Dig Dis Sci. 2016 Feb;61(2):489-500
26386862
CA Cancer J Clin. 2015 Mar;65(2):87-108
25651787
Oncogene. 2013 Oct 10;32(41):4873-82
23160379
J Gastroenterol. 2014 Mar;49(3):408-18
23591767
Oncogene. 2010 Sep 2;29(35):4947-58
20562913
Mol Cell. 2008 Mar 28;29(6):755-66
18374649
J Biol Chem. 2003 Aug 15;278(33):30788-95
12794076
Mol Cell. 2004 Oct 22;16(2):245-55
15494311
Am J Med Genet A. 2015 Jan;167A(1):164-8
25425123
Carcinogenesis. 2014 Aug;35(8):1707-16
24480807
Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):19796-801
22089237
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
21296855
Nat Med. 2006 Aug;12(8):933-8
16862154
J Hum Genet. 2014 Oct;59(10):581-3
25102098